Coherent (COHR) Q3 2026 Earnings Transcript

Coherent reported Q3 revenue of $1.8 billion, up 7% sequentially and 21% year over year, while non-GAAP EPS rose 55% year over year to $1.41 and gross margin expanded to 39.6% (+105 bps y/y). Management raised the OCS market opportunity to over $4 billion, said record backlog now extends into calendar 2028, and guided Q4 revenue to $1.91 billion-$2.05 billion with EPS of $1.52-$1.72. The company also highlighted a $2 billion NVIDIA equity investment and multiyear supply agreement, plus rapid indium phosphide capacity expansion that is expected to support further growth and margin improvement.

Analysis

This print is less about “AI demand is strong” and more about a supply-chain re-rating for photonics content. The critical second-order effect is that Coherent is moving from being a bottlenecked supplier to a capital-intensity flywheel: customer-funded LTAs plus upstream integration reduce near-term volume risk while simultaneously pulling forward capex and lock-in. That should disproportionately pressure smaller transceiver and component vendors that lack internal indium phosphide, because the pricing/power-efficiency gap is now being monetized through multi-year supply commitments rather than spot-cycle pricing.

The market is likely underappreciating how quickly gross margin can compound once 6-inch yield continues to outrun 3-inch. If 6-inch output becomes half of capacity by year-end, the mix shift alone can create a step-up in margin even before the new product ramps arrive; that means current consensus may still be modeling too linear an inflection. The more important read-through for NVDA is that this is evidence of vendor ecosystem de-risking, not just one supply agreement—NVIDIA is effectively helping finance an alternate optics stack that reduces single-source fragility across future AI cluster builds.

The main risk is timing slippage on the newer platforms. CPO, multi-rail, and thermal are all real, but they are still qualification-heavy and can move from “promising” to “revenue later” quickly if customer specs change or if broader AI capex pauses. Also, Coherent is now spending aggressively into capacity before all of the revenue is visible, so any temporary utilization miss would hit incremental margin harder than the headline numbers suggest.

Consensus may still be too cautious on the duration of the growth leg, but too optimistic on the smoothness of the ramp. The stock deserves a structural re-rate if investors believe backlog visibility through 2028 is real; however, the cleaner expression is likely in a basket trade versus more vertically exposed optics peers, because Coherent is capturing the highest-value layers while also self-funding the manufacturing moat.

Key Decisions for Investors

• Go long COHR on a 3-6 month horizon; use pullbacks after post-earnings digestion to build. Thesis: backlog + internal capacity expansion can drive sequential beats while margin expands faster than revenue. Risk/reward is attractive if the market starts discounting 2027 growth earlier.
• Pair trade: long COHR / short a weaker optics or module peer with less internal photonics integration over the same horizon. Objective is to isolate supply-chain integration and LTA benefits while hedging sector beta; expect relative outperformance if pricing stays firm and indium phosphide remains tight.
• Add NVDA exposure tactically via calls or existing core long, but treat COHR as the higher-beta supply-chain beneficiary. The read-through is positive for NVDA ecosystem durability; the trade is best as a medium-dated call spread into any AI infrastructure rerate.
• Sell premium via COHR put spreads 2-3 months out only if implied vol spikes on any capex or execution scare. The company’s near-term revenue visibility is high enough that downside is more likely to be shallow unless guidance is cut.
• Avoid chasing the newest product narratives as standalone longs until revenue timing is clearer; if you want exposure to CPO/multi-rail upside, own COHR rather than trying to pick early-stage enablers with less balance-sheet support.